Trial to Examine the Effect of Two Doses of GRI-0621 in Patients With Chronic Liver Disease

NCT02949375 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

14

Enrollment

INDUSTRY

Sponsor class

Stopped Administrative decision

Conditions

Chronic Liver Disease

Interventions

DRUG: Placebo Comparator
DRUG: Active Comparator:4.5mg GRI-0621
DRUG: Active Comparator: 6.0mg GRI-0621

Sponsor

GRI Bio Operations, Inc.